We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teleflex's (TFX) Q1 Earnings Top Estimates, Margins Down
Read MoreHide Full Article
Teleflex Incorporated’s (TFX - Free Report) adjusted earnings per share (EPS) from continuing operations of $2.88 for the first quarter of 2022 rose 5.5% year over year. The bottom line beat the Zacks Consensus Estimate by a penny.
GAAP EPS of $1.63 in the first quarter showed a 3.2% improvement from the year-ago figure.
Revenues in Detail
Net revenues in the first quarter improved 1.2% year over year to $641.7 million and 3.2% on a constant exchange rate or CER. The top line surpassed the Zacks Consensus Estimate by 1.6%.
Americas’ net revenues of $378 million increased 0.7% from the year-ago period and 0.8% at CER. In the quarter, surgical was the biggest contributor to growth, partially offset by the impact of COVID-19 and one less selling day. Excluding the impact of the selling day, the Americas region grew approximately 2.3% year over year.
Teleflex Incorporated Price, Consensus and EPS Surprise
EMEA net revenues of $136.9 million declined 3.1% year over year and improved 3.4% at CER. Interventional, Vascular Access, and Anesthesia products witnessed growth. EMEA continued to face a headwind from COVID-19 in early January and subsequently saw procedure volumes improvement as countries across the region opened up.
Revenues from Asia grew 8.6% and rose 12.5% on a CER basis year over year to $69.2 million.
Segmental Revenues
In the first quarter, the Vascular Access segment reported net revenues of $166.1 million, up 3.2% at CER. The Interventional business registered net revenues of $96.9 million, up 2.3% at CER.
Within the Anesthesia segment, net revenues improved 5% at CER to $86.9 million. The Surgical segment recorded net revenues of $89.7 million, reflecting an increase of 14.4% year over year at CER. Revenues of $74.9 million in the Interventional Urology segment rose 2.2% at CER.
Meanwhile, OEM recorded revenue growth of $57.7 million, up 9.2% at CER. The Other product segment’s (consisting of the company’s respiratory products that were not included in the divestiture to Medline, manufacturing service agreement revenues and Urology Care products) net revenues of $69.5 million registered a decline of 11.7% year over year at CER.
Margins
In the reported quarter, gross profit totaled $346.2 million, up 0.5% year over year. The gross margin contracted 39 basis points (bps) to 53.9%.
Overall, the adjusted operating profit was $105.9 million, down 4.9% year over year. Adjusted operating margin saw a 107-bp contraction year over year to 16.5%.
Liquidity Position
Teleflex exited 2022 with cash and cash equivalents of $466.7 million, up from $445 million at the end of 2021.
Cumulative cash flow provided by operating activities from continuing operations at the end of the first quarter of 2022 was $62.1 million compared with $110.8 million in the year-ago period.
Teleflex reiterated its 2022 non-GAAP financial guidance.
GAAP revenue growth for 2022 is reiterated in the range of 2.30-3.80% from the comparable figure in 2021. The company restated its constant currency revenue growth for 2022 in the band of 4.00-5.50% year over year. The current Zacks Consensus Estimate for total revenues is pegged at $2.90 billion.
The company reiterated its adjusted EPS from continuing operations projection for 2022 between $13.70 and $14.30, suggesting an increase of 2.8-7.3% from the comparable reported figure in 2020. The Zacks Consensus Estimate for the same is currently pegged at $14.01.
Our Take
Teleflex exited the first quarter of 2022 with better-than-expected results. The company exhibited year-over-year growth across the Americas, EMEA and Asia regions at CER. The company’s reiterated revenue and adjusted EPS outlook for 2022, reflecting promising results compared to 2021, instills investors’ confidence.
However, a year-over-year decline in the company’s Other product segment is concerning. The ongoing COVID-19 headwinds continue to hamper UroLift procedures, further raising apprehension. Escalating operating expenses are building pressure on margins.
Zacks Rank and Other Key Picks
Teleflex currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Qiagen N.V. (QGEN - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) and Centene Corporation (CNC - Free Report) .
Qiagen, carrying a Zacks Rank #2, reported first-quarter 2022 adjusted EPS of 80 cents, which beat the Zacks Consensus Estimate by 12.7%. Revenues of $628.4 million outpaced the consensus mark by 6.5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Qiagen has an estimated long-term growth rate of 11.5%. QGEN’s earnings surpassed estimates in the trailing four quarters, the average surprise being 11.7%.
UnitedHealth, having a Zacks Rank #2, reported first-quarter 2022 adjusted EPS of $5.49, which beat the Zacks Consensus Estimate by 1.7%. Revenues of $80.1 billion outpaced the consensus mark by 14.2%.
UnitedHealth has an estimated long-term growth rate of 14.8%. UNH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.7%.
Centene reported first-quarter 2022 adjusted EPS of $1.83, which surpassed the Zacks Consensus Estimate by 8.9%. First-quarter revenues of $80.1 billion outpaced the Zacks Consensus Estimate by 1.9%. It currently has a Zacks Rank #2.
Centene has an estimated long-term growth rate of 14.2%. CNC has an earnings yield of 6.6% compared with the industry’s 5.6%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Teleflex's (TFX) Q1 Earnings Top Estimates, Margins Down
Teleflex Incorporated’s (TFX - Free Report) adjusted earnings per share (EPS) from continuing operations of $2.88 for the first quarter of 2022 rose 5.5% year over year. The bottom line beat the Zacks Consensus Estimate by a penny.
GAAP EPS of $1.63 in the first quarter showed a 3.2% improvement from the year-ago figure.
Revenues in Detail
Net revenues in the first quarter improved 1.2% year over year to $641.7 million and 3.2% on a constant exchange rate or CER. The top line surpassed the Zacks Consensus Estimate by 1.6%.
Americas’ net revenues of $378 million increased 0.7% from the year-ago period and 0.8% at CER. In the quarter, surgical was the biggest contributor to growth, partially offset by the impact of COVID-19 and one less selling day. Excluding the impact of the selling day, the Americas region grew approximately 2.3% year over year.
Teleflex Incorporated Price, Consensus and EPS Surprise
Teleflex Incorporated price-consensus-eps-surprise-chart | Teleflex Incorporated Quote
EMEA net revenues of $136.9 million declined 3.1% year over year and improved 3.4% at CER. Interventional, Vascular Access, and Anesthesia products witnessed growth. EMEA continued to face a headwind from COVID-19 in early January and subsequently saw procedure volumes improvement as countries across the region opened up.
Revenues from Asia grew 8.6% and rose 12.5% on a CER basis year over year to $69.2 million.
Segmental Revenues
In the first quarter, the Vascular Access segment reported net revenues of $166.1 million, up 3.2% at CER. The Interventional business registered net revenues of $96.9 million, up 2.3% at CER.
Within the Anesthesia segment, net revenues improved 5% at CER to $86.9 million. The Surgical segment recorded net revenues of $89.7 million, reflecting an increase of 14.4% year over year at CER. Revenues of $74.9 million in the Interventional Urology segment rose 2.2% at CER.
Meanwhile, OEM recorded revenue growth of $57.7 million, up 9.2% at CER. The Other product segment’s (consisting of the company’s respiratory products that were not included in the divestiture to Medline, manufacturing service agreement revenues and Urology Care products) net revenues of $69.5 million registered a decline of 11.7% year over year at CER.
Margins
In the reported quarter, gross profit totaled $346.2 million, up 0.5% year over year. The gross margin contracted 39 basis points (bps) to 53.9%.
Overall, the adjusted operating profit was $105.9 million, down 4.9% year over year. Adjusted operating margin saw a 107-bp contraction year over year to 16.5%.
Liquidity Position
Teleflex exited 2022 with cash and cash equivalents of $466.7 million, up from $445 million at the end of 2021.
Cumulative cash flow provided by operating activities from continuing operations at the end of the first quarter of 2022 was $62.1 million compared with $110.8 million in the year-ago period.
The company has a dividend payout ratio of 10% at present.
2022 View
Teleflex reiterated its 2022 non-GAAP financial guidance.
GAAP revenue growth for 2022 is reiterated in the range of 2.30-3.80% from the comparable figure in 2021. The company restated its constant currency revenue growth for 2022 in the band of 4.00-5.50% year over year. The current Zacks Consensus Estimate for total revenues is pegged at $2.90 billion.
The company reiterated its adjusted EPS from continuing operations projection for 2022 between $13.70 and $14.30, suggesting an increase of 2.8-7.3% from the comparable reported figure in 2020. The Zacks Consensus Estimate for the same is currently pegged at $14.01.
Our Take
Teleflex exited the first quarter of 2022 with better-than-expected results. The company exhibited year-over-year growth across the Americas, EMEA and Asia regions at CER. The company’s reiterated revenue and adjusted EPS outlook for 2022, reflecting promising results compared to 2021, instills investors’ confidence.
However, a year-over-year decline in the company’s Other product segment is concerning. The ongoing COVID-19 headwinds continue to hamper UroLift procedures, further raising apprehension. Escalating operating expenses are building pressure on margins.
Zacks Rank and Other Key Picks
Teleflex currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Qiagen N.V. (QGEN - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) and Centene Corporation (CNC - Free Report) .
Qiagen, carrying a Zacks Rank #2, reported first-quarter 2022 adjusted EPS of 80 cents, which beat the Zacks Consensus Estimate by 12.7%. Revenues of $628.4 million outpaced the consensus mark by 6.5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Qiagen has an estimated long-term growth rate of 11.5%. QGEN’s earnings surpassed estimates in the trailing four quarters, the average surprise being 11.7%.
UnitedHealth, having a Zacks Rank #2, reported first-quarter 2022 adjusted EPS of $5.49, which beat the Zacks Consensus Estimate by 1.7%. Revenues of $80.1 billion outpaced the consensus mark by 14.2%.
UnitedHealth has an estimated long-term growth rate of 14.8%. UNH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.7%.
Centene reported first-quarter 2022 adjusted EPS of $1.83, which surpassed the Zacks Consensus Estimate by 8.9%. First-quarter revenues of $80.1 billion outpaced the Zacks Consensus Estimate by 1.9%. It currently has a Zacks Rank #2.
Centene has an estimated long-term growth rate of 14.2%. CNC has an earnings yield of 6.6% compared with the industry’s 5.6%.